Concepedia

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

A. Jo Chien, Julie Illi, Andrew H. Ko, W. Michael Korn, Lawrence Fong, Lee-may Chen, Mohammed Kashani–Sabet, Charles J. Ryan, Jonathan E. Rosenberg, Sarita Dubey,

Clinical Cancer Research · 2009 · 49 citations · 32 references

DOIFull text

Open access

Abstract

A 2-day pulse of high-dose lapatinib given before weekly nab-paclitaxel is a feasible and tolerable clinical regimen, suitable for testing this novel vascular-priming chemosensitization hypothesis developed in preclinical models.

References

32

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3K citations · Full text

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone, Roy S. Herbst, Christian Manegold et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text